0 likes | 3 Views
Our latest report provides a detailed analysis of the Sarcopenia market size, growth forecast, and latest trends. It covers the market trends, growth prospects, investment opportunities, and industry prospects. The report also includes an overview of the disease, market scenario, and growth trends. It further offers competitor analysis, regional analysis, and recent advancements in the Sarcopenia market.
E N D
ABOUT IMARC International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all regions and industry verticals to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
Report Description and Highlights Sarcopenia Market Report Overview: • Report Attribute Details • Base Year 2023 • Forecast Years 2024-2034 • Historical Years 2018-2023 • Market Size in 2023 US$ 1.5 Billion • Market Forecast in 2034 US$ 2.3 Billion • Market Growth (2024-2034) 4.1% The report offers a comprehensive analysis of the Sarcopenia market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report.
Report Description and Highlights This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the Sarcopenia market. Market Overview: The 7 major sarcopenia markets reached a value of US$ 1.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.1% during 2024-2034.
Report Description and Highlights The sarcopenia market is gaining increasing attention and investment due to a convergence of factors. Sarcopenia, characterized by muscle loss and decreased strength, often accompanied by reduced functionality in older adults, is at the center of this growing interest. One of the primary drivers fueling the expansion of the sarcopenia market is the rise in the aging population. As the proportion of geriatric individuals continues to grow, age-related conditions like sarcopenia become more prevalent, leading to a higher demand for interventions and treatments. Awareness campaigns and extensive scientific research on muscle decline associated with aging are driving interest and funding in the sarcopenia market. This has resulted in the development of specialized exercise programs, pharmaceuticals, and nutritional supplements designed to alleviate symptoms. Innovations in diagnostic methods, including DXA scans and MRI, have enhanced the detection and monitoring of sarcopenia, enabling timely intervention, which is crucial for effective treatment. In certain regions, healthcare policies have been revised to encompass treatments for age-related conditions, offering financial incentives to individuals seeking treatment. This policy shift further augments the market potential for sarcopenia products and services. The recent emphasis on preventive healthcare and wellness has created a conducive environment for addressing the onset and progression of sarcopenia.
Report Description and Highlights Protein supplements and exercise equipment tailored to build muscle mass in older adults are gaining popularity. Additionally, the increased utilization of resistance and strength training to treat the condition by enhancing muscle protein synthesis and supporting muscular strength is another significant growth-inducing factor. Collaborations between academic institutions, healthcare providers, and biotech companies are expediting research and product development, which is expected to contribute significantly to the growth of the sarcopenia market in the coming years. Request a Sample Report: https://www.imarcgroup.com/sarcopenia-market/requestsample
Report Description and Highlights What is included in the report segmentation? The report covers the following aspects: Report Period: • Base Year: 2023 • Historical Period: 2018-2023 • Market Forecast: 2024-2032 Countries Included: • United States • Germany • France
Report Description and Highlights • United Kingdom • Italy • Spain • Japan Analysis Covered Across Each Country: • Historical, current, and future epidemiology scenario • Historical, current, and future performance of the Sarcopenia market • Historical, current, and future performance of various therapeutic categories in the market • Sales of various drugs across the Sarcopenia market • Reimbursement scenario in the market • In-market and pipeline drugs This report also provides a detailed analysis of the current Sarcopenia marketed drugs and late-stage pipeline drugs.
Report Description and Highlights In-Market Drugs: • Drug Overview • Mechanism of Action • Regulatory Status • Clinical Trial Results • Drug Uptake and Market Performance Late-Stage Pipeline Drugs: • Drug overview • Mechanism of action • Regulatory status • Clinical trial results • Drug uptake and market performance View Report TOC, Figures and Tables: https://www.imarcgroup.com/sarcopenia-market
Report Description and Highlights Competitive Landscape With Key Players: The competitive landscape of the Sarcopenia market has been studied in the report with the detailed profiles of the key players operating in the market. Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=7323&flag=C If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization. About Us IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Report Description and Highlights Media Contact: Company Name: IMARC Group Contact Person: Elena Anderson Email: sales@imarcgroup.com Phone: +1-631-791-1145 Address: 134 N 4th St City: Brooklyn State: NY Country: United States Website: https://www.imarcgroup.com/
Key Questions Answered in the Report • How has the Sarcopenia market performed so far and how will it perform in the coming years? • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034? • What was the country-wise size of the Sarcopenia market across the seven major markets in 2023 and what will it look like in 2034? • What is the growth rate of the Sarcopenia market across the seven major markets and what will be the expected growth over the next ten years? • What are the key unmet needs in the market?
Table of Contents 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary
Table of Contents 4 Sarcopenia - Introduction 4.1 Overview 4.2 Regulatory Process 4.3 Epidemiology (2018-2023) and Forecast (2024-2034) 4.4 Market Overview (2018-2023) and Forecast (2024-2034) 4.5 Competitive Intelligence 5 Sarcopenia - Disease Overview 5.1 Introduction 5.2 Symptoms and Diagnosis 5.3 Pathophysiology 5.4 Causes and Risk Factors 5.5 Treatment Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/sarcopenia-market/toc
Disclaimer © 2024 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC). Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication. IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.